CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 1,101 enrolled
Drug / intervention
Poliorix™ +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01021293
NCT01021293Phase 3Completed
CompareCT.gov

Immunogenicity and Safety of GSK Biologicals' IPV (Poliorix™) in Infants

GlaxoSmithKline·interventional·Posted Nov 26, 2009·Updated Jan 21, 2020

In Brief

A Phase 3 clinical trial evaluating Poliorix™ and Oral Poliovirus vaccine for Poliomyelitis and Poliomyelitis Vaccines. Completed, enrolled 1,101 participants across 1 site.

Detailed Summary

The purpose of the study is to evaluate the immunogenicity and safety of Poliorix™ when administered to healthy Chinese infants at 2, 3 and 4 months of age.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPoliomyelitis, Poliomyelitis Vaccines
CountriesChina
Collaborators--

Timeline

Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedNov 26, 2009
Enrollment StartNov 28, 2009
Primary CompletionJul 5, 2010
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 16.6 years ago

Interventions

Poliorix™biological

3 doses, intramuscular administration

Oral Poliovirus vaccinebiological

3 doses, oral administration